Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Xenoport (XNPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 447,590
  • Shares Outstanding, K 63,520
  • Annual Sales, $ 41,160 K
  • Annual Income, $ -82,310 K
  • 36-Month Beta 1.94
  • Price/Sales 10.87
  • Price/Cash Flow 0.00
  • Price/Book 56.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.21
  • Most Recent Earnings -0.23 on 05/05/16
  • Next Earnings Date 08/03/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.96 +1.58%
on 06/13/16
7.07 unch
on 07/05/16
unch (unch)
since 06/03/16
3-Month
3.90 +81.28%
on 05/12/16
7.10 -0.42%
on 06/01/16
+2.22 (+45.77%)
since 04/05/16
52-Week
3.35 +111.04%
on 09/30/15
7.86 -10.05%
on 08/04/15
+0.75 (+11.87%)
since 07/02/15

Most Recent Stories

More News
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,...

XNPT : 7.07 (+0.71%)
ACRX : 2.55 (-5.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.

See More

Support & Resistance

2nd Resistance Point 7.10
1st Resistance Point 7.09
Last Price 7.07
1st Support Level 7.04
2nd Support Level 7.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.